Overview
SINTX Q3 revenue of $0.2 mln missed analyst expectations
Operating expenses decreased 51% yr/yr, reducing operating loss to $3.4 mln
Company strengthened liquidity with $4.3 mln raised through warrant exercises
Outlook
SINTX plans to launch the SINAPTIC wedge system in the near term
Company aims to expand clinical engagement in targeted surgical specialties
SINTX intends to leverage material science for polymer composites in implants
Result Drivers
FIRST PRODUCT REVENUE - Recorded initial revenue from OsseoSculpt, a private-labeled orthobiologic product
FACILITY OPTIMIZATION - Subleased Armor facility, saving up to $950,000 in lease costs
STRENGTHENED LIQUIDITY - Raised $4.3 mln through warrant inducement and exercises
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Miss | $200,000 | $400,000 (1 Analyst) |
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for SINTX Technologies Inc is $25.00, about 86.3% above its November 12 closing price of $3.43
Press Release: ID:nGNX3fwCk3
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)